出品｜搜狐财经 作者｜柴鑫洋 编辑｜李文贤 4月28日，沪上阿姨启动港股招股。 据了解，沪上阿姨此次在港上市拟全球发售约241万股H股，每股95.57港元/股至113.12港元/股。预期5月6日定价，5月8日开始在港交所交易。代码为 2589。 据灼识咨询资料，按2023年的GMV计算，沪上阿姨是中国第五大茶饮品牌，市场份额为4.6%。排在公司前面的分别是蜜雪冰城（20.2%）、古茗 （9.1%）、茶百道（8.0%）、霸王茶姬（5.0%）。 中国食品产业分析师朱丹蓬表示，新中式奶茶的竞争已经进入了全方位、多维度的竞争周期。如今的茶饮市场，既有门店数量的规模化竞争，也有品牌效 应的竞争，更多的则是在供应链体系上的竞争。 拟全球发售241万股H股，5月8日在港交所交易 沪上阿姨4月28日早间公告，在港上市拟全球发售约241万股H股，每股95.57港元/股至113.12港元/股。预期5月6日定价，5月8日开始在港交所交易。代码 为2589。 4月23日，沪上阿姨通过港交所上市聆讯。 搜狐财经注意到，去年情人节当天，沪上阿姨第一次向港交所递交招股书，年底，沪上阿姨又再次向递表。 沪上阿姨在招股书中表示，IPO募集所得 ...

4月28日，泡泡玛特(09992.HK)股价盘中一度暴涨超13%，达到195港元的历史新高，市值突破2600亿港 元。这一资本市场的热烈反响，与该公司旗下核心IP"LABUBU"第三代产品全球发售引发的消费热潮密 切相关。 4月24日，泡泡玛特旗下人气IP"LABUBU"在全球发售第三代搪胶毛绒产品"前方高能"系列，引发了全 球抢购风潮。发售当晚，"抢LABUBU"等相关词条便迅速登顶微博热搜，国内线上一经开售秒速售罄， 美国芝加哥、美国洛杉矶、英国伦敦及日本原宿等地的海外线下门店外连夜排起长龙。受此影响，泡泡 玛特官方APP下载量激增。七麦数据显示，4月25日，泡泡玛特APP首次登顶美国App Store购物榜，并 一跃成为了App Store免费总榜的第四名。 LABUBU的走红，颠覆了传统潮玩"可爱治愈"的审美逻辑。这只由香港艺术家龙家升设计的精灵，凭借 尖锐耳朵、夸张獠牙和搞怪表情，精准击中了Z世代追求个性表达的情绪需求。2024年以来，韩国女团 BLACKPINK成员Lisa的随身佩戴、国际巨星蕾哈娜的机场街拍，让LABUBU在社交媒体上迅速传播， 积累了极高的人气，泰国文旅部门甚至授予其"文旅体验 ...

4月28日，财政部公布数据，截至2025年3月末，全国地方政府债务余额501650亿元。其中，一般债务 170225亿元，专项债务331425亿元；政府债券500046亿元，非政府债券形式存量政府债务1604亿元。 截至2025年3月末，地方政府债券剩余平均年限10.0年，其中一般债券5.9年，专项债券12.2年；平均利 率2.99%，其中一般债券3.08%，专项债券2.95%。 ...

Group 1 - Northbound capital recorded a net purchase of 20.3 billion HKD in the Hong Kong stock market on April 28, with the Shanghai-Hong Kong Stock Connect seeing a net purchase of 23.43 billion HKD and the Shenzhen-Hong Kong Stock Connect experiencing a net sale of 3.13 billion HKD [1] - The stocks with the highest net purchases included the Tracker Fund of Hong Kong (02800), Hang Seng China Enterprises (02828), and CanSino Biologics (09926) [1] - The stocks with the highest net sales were Alibaba-W (09988), Tencent (00700), and Xiaomi Group-W (01810) [1] Group 2 - CanSino Biologics (09926) received a net purchase of 7.79 billion HKD, with a report indicating positive results from its clinical trial for the dual-specific antibody AK112 in treating advanced squamous non-small cell lung cancer [5] - Meituan-W (03690) saw a net purchase of 5.56 billion HKD, with analysts noting that the company does not face risks of ADR delisting and has stable revenue sources [5] - China Shenhua (01088) had a net purchase of 5.17 billion HKD, with analysts highlighting its strong cash flow supporting high dividend payouts despite pressure from falling coal prices [6] Group 3 - The Tracker Fund of Hong Kong (02800) and Hang Seng China Enterprises (02828) received net purchases of 20.43 billion HKD and 12.5 billion HKD, respectively, indicating increased investor confidence [4] - Tencent (00700) and Alibaba-W (09988) faced net sales of 5.97 billion HKD and 14.24 billion HKD, respectively, amid concerns regarding the ongoing US-China trade tensions [6] - China Mobile (00941) received a net purchase of 1.13 billion HKD, while Xiaomi Group-W (01810) and SMIC (00981) experienced net sales of 2.56 billion HKD and 1.36 billion HKD, respectively [6]

中国经济网北京4月28日讯阳光保险(06963.HK)港股今日收盘报3.42港元，跌幅2.29%。 公告显示，最终发售价定为每股发售股份5.83港元(不包括1.0%经纪佣金、0.0027%证监会交易征费、 0.00015%会财局交易征费及0.005%香港联交所交易费)。按最终发售价计算，经扣除公司就全球发售应 付的承销佣金及其他估计开支后，公司收取的全球发售所得款项净额约为6,419.5百万港元。 阳光保险港股目前处于破发状态。 南方都市报在报道《阳光保险两年多市值蒸发200亿港元》中指出，截至4月25日收盘报3.50港元，相较 上市时的发行价5.83港元下跌40%，市值蒸发超200亿港元。股价的持续低迷也对公司员工持股计划构 成压力。2016年2月，阳光保险曾召开股东大会，向核心员工配发了4.4亿股内资股，认购价为4元人民 币/股，并规定上市后三年内不得出售，锁定期满后每年减持不超过25%。这意味着员工持有的股票要 到2025年12月9日才能卖出。然而，如今阳光保险股价早已跌破认购价，导致参与计划的3688名员工面 临亏损。 阳光保险2025年4月25日发布2024年年报显示，集团总保费收入1,283.8亿 ...

南向资金今日净买入20.3亿元。港股通（沪）方面，康方生物、盈富基金分别获净买入11.38亿港元、 10.29亿港元；阿里巴巴-W净卖出额居首，金额为8.84亿港元；港股通（深）方面，恒生中国企业、盈 富基金分别获净买入12.51亿港元、10.14亿港元；阿里巴巴-W净卖出额居首，金额为5.41亿港元。 ...

近日,通用环球医疗集团有限公司("环球医疗",2666.HK)正式发布《2024年度环境、社会及管治(ESG)报 告》,系统披露了环球医疗履行环境、社会及管治责任的理念与实践,积极回应了主要利益相关方所关注 的重要议题。 2024年,环球医疗将董事会下属战略委员会正式更名为战略与ESG委员会,首次制定了公司级ESG战略体 系,标志着ESG建设迈入了战略驱动的更高阶段。围绕"以科技进步和品质服务引领美好生活"的企业使 命,环球医疗通过将ESG理念融入公司战略运营与管理体系中,打造可持续的公司治理,努力实现企业发展 与为人民服务相协调、与员工成长相协调、与环境可持续发展相协调,及与利益相关方共赢。 作为央企办医的代表性企业,环球医疗长期深耕对人类文明进程具有深远意义和持久价值的医疗健康领 域,锚定国家战略方向,在助力健康中国建设、服务实体经济、推动产业升级、促进民生改善中勇担使命, 探索"医、产、融"深度协同的高质量发展路径。 2024年,环球医疗再次入选央视"中国ESG上市公司先锋100"榜单,位列第63位;公司的标普全球ESG得分大 幅提升至61分,位居国内细分行业第一名(全球前10%)。近日,环球医疗成功入 ...

"五一"假期临近，国内市场即将迎来旅游餐饮消费高峰。海底捞后台数据显示，假期期间的用餐预订单 量正在快速上升，截至4月28日，全国门店已接到假期首日预订超2.5万桌。层出不穷的新场景、新玩 法、新产品，为消费者的假期带来了更多惊喜。(36氪) ...

Core Viewpoint - The China Securities Index for Hong Kong Stock Connect Medical Devices shows a recent decline, but has experienced significant growth over the past three months and year-to-date [1]. Group 1: Index Performance - The China Securities Index for Hong Kong Stock Connect Medical Devices reported a recent value of 1194.94 points [1]. - Over the past month, the index has decreased by 3.48%, while it has increased by 15.43% over the last three months and 12.63% year-to-date [1]. Group 2: Index Composition - The index is composed entirely of securities listed on the Hong Kong Stock Exchange, with a sample that includes various sectors classified under the China Securities Industry Classification Standard [2]. - The index's sample shows that medical consumables account for 79.10%, medical devices for 16.57%, and in vitro diagnostics for 4.34% [2]. Group 3: Index Adjustments - The index samples are adjusted biannually, specifically on the second Friday of June and December, with weight factors fixed until the next scheduled adjustment [2]. - In cases of special events affecting the index sample, such as delisting or mergers, adjustments will be made accordingly [2].

Group 1 - The core viewpoint of the article highlights the performance of the CSI Hong Kong-Shanghai Biotech Theme Index, which reflects the overall performance of listed companies in the biotech sector from mainland China and Hong Kong [1][3] - The CSI Hong Kong-Shanghai Biotech Theme Index has shown an increase of 0.82% over the past month, 12.93% over the past three months, and 12.21% year-to-date [1] - The index consists of 50 sample companies involved in biopharmaceuticals, pharmaceuticals, and biotech services, with a base date of December 28, 2018, set at 1000.0 points [1] Group 2 - The top ten weighted companies in the index include: Heng Rui Medicine (13.16%), BeiGene (10.43%), WuXi AppTec (8.41%), Mindray Medical (7.71%), WuXi Biologics (5.15%), Innovent Biologics (4.82%), CanSino Biologics (3.91%), Shanghai Pharmaceuticals (2.74%), China National Pharmaceutical Group (2.45%), and Shanghai RAAS Blood Products (1.83%) [1] - The market share of the index holdings is distributed as follows: Hong Kong Stock Exchange 41.72%, Shanghai Stock Exchange 35.62%, and Shenzhen Stock Exchange 22.66% [1] Group 3 - In terms of industry composition, biopharmaceuticals account for 43.26%, chemical drugs for 25.78%, pharmaceutical and biotech services for 21.39%, and medical devices for 9.57% [2] - The index samples are adjusted semi-annually, with adjustments occurring on the next trading day after the second Friday of June and December each year [2] - Special circumstances may lead to temporary adjustments to the index, including the removal of samples that are delisted or changes due to mergers, acquisitions, or other corporate actions [2]